Back to Search
Start Over
Pegylated liposomal doxorubicin combined with carboplatin: A rational treatment choice for advanced ovarian cancer
- Source :
-
Critical Reviews in Oncology/Hematology . Jan2010, Vol. 73 Issue 1, p23-30. 8p. - Publication Year :
- 2010
-
Abstract
- Abstract: Objective: Many questions remain unanswered regarding the optimal treatment paradigm for ovarian cancer, and alternatives for both first- and second-line therapy are needed. Methods: This review summarizes recent data with the combination of pegylated liposomal doxorubicin (PLD) and carboplatin in ovarian cancer. Results: Anthracyclines are active in ovarian cancer and lack the neurotoxic effects of taxanes. PLD has reduced cardiotoxic potential vs non-liposomal doxorubicin and is the only non-platinum monotherapy to demonstrate a significant survival advantage as second-line treatment of ovarian cancer. Replacing the taxane with PLD in platinum doublets for either first-line or recurrent ovarian cancer (ROC) has been or is being evaluated in more than 1600 patients. Studies evaluating PLD plus carboplatin in platinum-sensitive ROC have shown that the regimen is tolerable and active. Conclusion: PLD–carboplatin is a promising chemotherapy combination. Phase III trials will elucidate whether it represents a new standard of care in ovarian cancer. [Copyright &y& Elsevier]
Details
- Language :
- English
- ISSN :
- 10408428
- Volume :
- 73
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Critical Reviews in Oncology/Hematology
- Publication Type :
- Academic Journal
- Accession number :
- 46750109
- Full Text :
- https://doi.org/10.1016/j.critrevonc.2009.08.004